Skip to content
Catalyst

PapersPMID:34204220

Astaxanthin Protects Dendritic Cells from Lipopolysaccharide-Induced Immune Dysfunction.

Marine drugs2021The record ↗

findings
4
compound
1
endpoints
4
PMID:34204220
  1. Finding, very limited evidencelowersInterleukin-6 concentration
  2. Finding, very limited evidenceraisesNFE2L2
  3. Finding, very limited evidencelowersCCR7
  4. Finding, insufficient evidencelowersTumour necrosis factor alpha concentration
  • “The results showed that administration of astaxanthin significantly decreased the production of TNF-α, IL-6, and IL-10.”
  • Activates NFE2L2

    very limited

    “As shown in Figure 8A–D, treatment of LPS-induced DCs with astaxanthin, HO-1, and Nrf2 were significantly upregulated, compared with the LPS-only group.”
    Study
    in vitro · not in humans
    Population
    LPS-induced murine bone-marrow-derived dendritic cells
  • Inhibits CCR7

    very limited

    “With LPS treatment alone, CCR7 expression was significantly increased, whereas they remarkably declined after the treatment of astaxanthin.”
    Study
    in vitro · not in humans
    Population
    LPS-induced murine bone-marrow-derived dendritic cells

Study record

Design
animal study, in vivo
Species
mixed
Population
Murine bone-marrow-derived dendritic cells (from C57BL/6 mice) treated with LPS in vitro; and LPS-challenged male C57BL/6 mice in vivo
Participants
not reported
Comparator
not stated in the paper / placebo
Duration
not reported
Endpoints measured
14